ARIScience was founded with the goal of effecting positive societal change by reducing the burden of human disease. What differentiates us is our hypothesis, that unifying the disparate disciplines of AI, quantum chemistry, computer vision, and biochemistry is what will drive the next-generation of small molecule drugs.
We are passionate about developing innovative solutions for interrupting protein-protein interactions to treat a wide range of diseases. Our team of experienced scientists and drug discovery experts is dedicated to discovering novel small molecule inhibitors that directly or allosterically target protein-protein interactions implicated in disease.
Our approach to drug discovery is based on cutting-edge in silico methods, including molecular modeling, virtual screening, and machine learning algorithms. With these tools, we efficiently identify and optimize drug candidates with high potency, selectivity, and pharmacokinetic properties.
We are committed to collaborating with leading academic institutions and biopharmaceutical companies to advance our drug discovery programs and bring new treatments to patients in need. Our pipeline includes several promising candidates for a variety of therapeutic areas, including infectious diseases and neurodegenerative disorders.
At ARIScience, we are driven by a shared mission to improve the lives of patients through the discovery and development of innovative therapies. We believe that our unique expertise in protein interruption and our collaborative approach to drug discovery make us well-positioned to make a meaningful impact on human health.
ARIScience has assembled a diverse, capable team.
Founder, AI & Quantam Chemistry Expert
Ruhul Abid, MD PhD
Clinical Research Expert, Global Health Expert
Brian Garibaldi, MD
Acute Care Expert
Naved Munir, MD
Clinical Care Expert Hospitalist
Ala Shaqra, PhD
In-vitro Assay Expert
Former CMO of Xerox
Carolyn Bramante, MD MPH
Clinical Trial Expert, Internal Medicine Physician
How Can We Help You?
If you have a protein that is over-expressed or mutated that lies on a disease pathway we can help. We do it by analyzing the protein’s topological and formation energy features and using those features to find or construct cognate small molecule candidates that can interrupt the protein directly, allosterically or formatively.
We then take such candidates to in vitro confirmation based on either binding or activity based assays (e.g. FRET, thermal shift, or ITC). We then take in vitro validated candidates for in vivo murine model confirmation via qualified in vivo CROs.
In short, we can help find actionable promising lead small molecule therapeutic candidates!